- Latest digital platform provides key advancements to help
maintain high signal fidelity while reducing environmental
noise
- Forward-looking platform designed to help enable path to new
technologies in the electrophysiology (EP) lab
GE HealthCare (Nasdaq: GEHC) announces the latest innovation in
electrophysiology (EP), the Prucka 3 with CardioLab EP Recording
system, to help clinicians in the diagnosis and treatment of
cardiac arrhythmias.
Cardiovascular disease is the leading cause of death globally -
affecting millions of individuals and placing a significant burden
on healthcare systems today. 1 Within the complex umbrella of
cardiology care and cardiovascular disease, atrial fibrillation
(AFib) is the most common arrhythmia diagnosed in clinical practice
with projections indicating that the prevalence of AFib could reach
15.9 million people in the United States by 2050 and 17.9 million
in Europe by 2060.2 For those living with cardiac arrhythmias like
AFib, the longer a person is living out of rhythm, the more
difficult the arrhythmia is to treat and the more dangerous it may
become. If diagnosed early, rhythm control treatment can reduce
AFib recurrence and potentially prevent progression.3
Electrophysiology labs play a pivotal role in the treatment of
cardiac arrhythmias like AFib and require sophisticated recording
systems to capture and analyze intracardiac signals accurately. GE
HealthCare’s latest Prucka 3 with CardioLab EP Recording system
builds on more than twenty years of success in the field of
electrophysiology to provide a robust ecosystem of mapping
technologies that help provide accurate, efficient, and advanced
analytics for the diagnosis and treatment of cardiac
arrhythmias.
The system’s digital platform maintains high signal fidelity,
while reducing environmental noise through new signal-filtering
capabilities and enhanced software for powerline noise reduction.4
The forward-looking platform also provides a path to emerging
technologies in electrophysiology that depend on quality signals
for their fast interpretation and clinical results.
“Signal clarity is key in the EP Lab,” shares Dr. Usman
Siddiqui, Director of Electrophysiology.5 “With the launch of the
latest Prucka 3 digital amplifier, I feel confident analyzing
critical signals regardless of the type of ablation technology or
platform I am using. Prucka 3 delivers the signal quality I expect
from CardioLab and GE HealthCare.”
‘‘The launch of the latest Prucka 3 digital amplifier is a game
changer for EP labs,” shares Devon Bream, General Manager of
Invasive Cardiology for GE HealthCare. “The new platform not only
provides beautiful signals, but the digital architecture continues
to demonstrate our commitment to give clinicians the tools, along
with the flexibility and adaptability, to enable better outcomes
for their patients. After serving the EP community for over 20
years, the latest Prucka 3 with CardioLab truly ‘amplifies’ the EP
Lab experience through a fully digital experience ready to enable
the future of electrophysiology.”
New features now available as part of the latest Prucka 3 with
CardioLab EP Recording system:
- Enhanced Signal Filtering Capabilities including
powerline harmonic removal;
- Dual Real-Time places a second real-time display on any
of the CardioLab display monitors;
- Cycle Length on Signal labels the cycle length directly
on the signal in real-time;
- Multiple Review Windows allow for the placement of up to
five review windows; and
- ClearMatch tags interesting morphology to create a
template that can be used in review to match the two
morphologies.
Prucka 3 with CardioLab EP Recording system is part of GE
HealthCare’s larger cardiology care portfolio to address
cardiovascular disease and key challenges faced in cardiology care
today. As part of this comprehensive care pathway approach, GE
HealthCare has made other recent enhancements to the portfolio
including the introduction of Allia IGS Pulse, the next generation
of image-guided systems designed for cardiac imaging excellence and
CardioVisio for Atrial Fibrillation which helps visualize the
history of the patient’s heart and provides guideline-directed
insights to healthcare providers.
More about GE HealthCare at AF Symposium 2024
GE HealthCare’s Exhibit Booth 213 will feature
opportunities for attendees to interact with the company’s latest
innovations, including the Prucka 3 with CardioLab EP Recording
system.
Live Case Presentation: On Saturday, February 3rd from
10:00 – 11:00 EST, attendees can view Dr. Saumil Oza, Director of
Electrophysiology, perform an Electrogram Dispersion Guided
Ablation procedure and present his experiences using Prucka 3 with
CardioLab EP Recording System and Volta technology.
“I am excited to highlight GE HeathCare’s latest EP clinical
innovation the Prucka 3 digital amplifier at this year’s AF
Symposium,” shares Dr. Saumil Oza.6 “EP recording systems and their
ability to record clear signals are critical to helping enable
advanced technologies in the field of EP.”
For more information on the latest innovations in invasive
cardiology, visit
https://www.gehealthcare.com/products/invasive-cardiology.
To learn more about GE HealthCare and the company’s
comprehensive suite of cardiology solutions, please visit
https://www.gehealthcare.com/specialties/cardiology.
This product may not be available in your country or region.
Please contact your GE HealthCare representative for more
information.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology,
pharmaceutical diagnostics, and digital solutions innovator,
dedicated to providing integrated solutions, services, and data
analytics to make hospitals more efficient, clinicians more
effective, therapies more precise, and patients healthier and
happier. Serving patients and providers for more than 100 years, GE
HealthCare is advancing personalized, connected, and compassionate
care, while simplifying the patient’s journey across the care
pathway. Together our Imaging, Ultrasound, Patient Care Solutions,
and Pharmaceutical Diagnostics businesses help improve patient care
from diagnosis, to therapy, to monitoring. We are an $18.3 billion
business with 50,000 employees working to create a world where
healthcare has no limits.
Follow us on Facebook, LinkedIn, Twitter, Instagram, and
Insights for the latest news, or visit our website
https://www.gehealthcare.com/ for more information.
1 World Health Organization (WHO) estimated 17.9 million people
died from cardiovascular diseases in 2019.
https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
2 Vinter N, Huang Q, Fenger-Grøn M, Frost L, Benjamin EJ,
Trinquart L. Trends in excess mortality associated with atrial
fibrillation over 45 years (Framingham Heart Study): community
based cohort study. BMJ. 2020 Aug 11;370:m2724. doi:
10.1136/bmj.m2724. PMID: 32784208; PMCID: PMC7418071.
3 Camm A, Naccarelli G, Mittal S, et al. The Increasing Role of
Rhythm Control in Patients With Atrial Fibrillation. J Am Coll
Cardiol. 2022 May, 79 (19) 1932–1948.
https://doi.org/10.1016/j.jacc.2022.03.337.
4 GE HealthCare Data on File
5 Dr. Siddiqui is a paid consultant for GE HealthCare and was
compensated for participation in this testimonial. The statements
by Dr. Siddiqui described here are based on his own opinions and on
results that were achieved in his unique setting. Since there is no
“typical” hospital and many variables exist, (i.e., hospital size,
case mix, etc.) there can be no guarantee that other customers will
achieve the same results.
6 Dr. Oza is a paid consultant for GE HealthCare and was
compensated for participation in this testimonial. The statements
by Dr. Oza described here are based on his own opinions and on
results that were achieved in his unique setting. Since there is no
“typical” hospital and many variables exist, (i.e., hospital size,
case mix, etc.) there can be no guarantee that other customers will
achieve the same results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240130382094/en/
Emily Dalton Niles - emily.niles@gehealthcare.com -
262-290-8089
GE HealthCare Technologies (NASDAQ:GEHC)
Historical Stock Chart
From Apr 2024 to May 2024
GE HealthCare Technologies (NASDAQ:GEHC)
Historical Stock Chart
From May 2023 to May 2024